Introduction to Indian Regulatory Requirements
This unit focuses on the Indian pharmaceutical regulatory framework. It covers the organization and responsibilities of CDSCO (Central Drug Standard Control Organization) and State Licensing Authorities, the Certificate of Pharmaceutical Product (COPP), and the regulatory requirements and approval procedures for new drugs in India. Understanding the Indian regulatory landscape is essential for pharmaceutical professionals working in or exporting from India.
Syllabus & Topics
- 1CDSCO – Organization: CDSCO (Central Drug Standard Control Organization): the national regulatory body for pharmaceuticals, cosmetics, and medical devices in India. Functions under the Ministry of Health & Family Welfare, Directorate General of Health Services. Head: Drugs Controller General of India (DCGI). Headquarters: FDA Bhawan, New Delhi. Structure: (1) Headquarters (New Delhi): policy, new drug approvals, import licenses, clinical trial approvals. (2) Zonal Offices (6): Mumbai, Kolkata, Chennai, Ghaziabad, Hyderabad, Ahmedabad — handle pre/post-market surveillance, import verification. (3) Sub-Zonal Offices (7): Chandigarh, Bangalore, etc. (4) Port Offices: at major ports/airports for import verification. Key bodies under CDSCO: DTAB (Drugs Technical Advisory Board): advises Central Government on technical matters. DCC (Drugs Consultative Committee): advises on uniform administration of the D&C Act.
- 2CDSCO – Responsibilities: Central Government responsibilities (via CDSCO): (1) Approval of NEW DRUGS (including new chemical entities, new combinations, new dosage forms, new routes). This is an EXCLUSIVE central function. (2) Approval of CLINICAL TRIALS. (3) Import registration and licensing: all drugs imported to India require CDSCO approval. (4) License for blood banks, large volume parenterals (LVP), vaccines, sera, r-DNA products. (5) Post-market surveillance and pharmacovigilance (PvPI — Pharmacovigilance Programme of India). (6) Scheduled drug regulation (Schedule X — narcotics). (7) Setting standards: pharmacopoeial standards through Indian Pharmacopoeia Commission (IPC). (8) Banning of drugs deemed unsafe (e.g., combination products with no rational basis). DCGI powers: approve/reject new drug applications, grant import licenses, suspend/cancel licenses for non-compliance, issue recall orders.
- 3State Licensing Authority: State Government responsibilities: (1) Licensing of manufacturing units (drug manufacturing licenses — Form 25/25-A under Schedule M). (2) Licensing of sale establishments (wholesale license — Form 20B, retail license — Form 20/21). (3) Inspection of manufacturing plants and retail pharmacies. (4) Enforcement of D&C Act at state level. (5) Sample collection and testing (government analyst). (6) Prosecution of offenders. Key positions: (1) State Drug Controller (SDC): heads the state drug control organization. (2) Drug Inspector (DI): field-level officer — inspects pharmacies, collects samples, files complaints. Powers: enter and inspect premises, collect samples, seize adulterated/spurious drugs, file complaints in court. (3) Government Analyst: tests drug samples collected by DI — issues test report (Form 13 — test certificate).
- 4Division of Powers – Central vs State: Dual regulatory system in India: CENTRAL (CDSCO): new drug approval, import, clinical trials, blood banks, vaccines, national standards. STATE (State FDA): manufacturing licenses, sale licenses, inspection, enforcement, prosecution. Challenges of dual system: (1) Coordination issues between central and state authorities. (2) Varying enforcement standards across states. (3) Some states more strict than others → uneven quality landscape. (4) Who approves a new combination? Previously state-level → led to irrational combinations. Now: all new drugs/combinations require CDSCO approval (59th Amendment to D&C Rules, 2015). Mashelkar Committee (2003): recommended restructuring — establishing a National Drug Authority. Ranjit Roy Chaudhury Committee (2013): recommended clinical trial reforms. Recent developments: centralized platform (SUGAM portal) for online regulatory submissions.
- 5COPP – Certificate of Pharmaceutical Product: COPP: Certificate of Pharmaceutical Product — issued by CDSCO. Based on WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce. Purpose: certifies that a pharmaceutical product manufactured in India: (1) Has a valid manufacturing license. (2) Manufacturing premises is subject to periodic inspection. (3) Product specifications comply with Indian Pharmacopoeia or approved standards. (4) Manufacturer follows GMP requirements. Why needed: required by many importing countries as proof that the product meets quality standards of the exporting country. Application: manufacturer applies to CDSCO with: product details, manufacturing license copy, GMP certificate, product registration details, CoA (Certificate of Analysis). COPP is product-specific and country-specific (issued for export to specific country). Validity: typically 2 years. Some countries accept COPP directly for product registration; others use it as supporting document.
- 6New Drug Approval in India: New drug (as per Schedule Y): (1) New chemical entity (NCE) or drug not previously approved in India. (2) New combination of already approved drugs. (3) Modified/new claims for approved drugs (new indication). (4) New dosage form/route of an approved drug. (5) Drugs already approved but proposed to be manufactured in India for the first time. Application process: (1) Preclinical data: pharmacology, toxicology (as per Schedule Y requirements). (2) Clinical trial permission: apply to CDSCO. Phase I, II, III trials in India (may be waived for drugs with substantial global data). New Drugs Advisory Committee evaluates application. (3) New Drug Application: submit complete data — CMC, preclinical, clinical, stability. (4) CDSCO evaluation: may seek expert opinions, request additional data. (5) Approval: manufacturing and marketing permission granted.
- 7New Drug Approval – Regulatory Changes: Recent regulatory reforms: (1) New Drugs and Clinical Trials Rules, 2019: comprehensive overhaul of clinical trial regulations. Key features: defined timelines for approvals (30/90 days), compensation framework for SAEs, academic clinical trials provisions, ethics committee registration. (2) Schedule Y → replaced by New Drugs and Clinical Trials Rules. (3) Accelerated approval pathway: for serious/life-threatening conditions. (4) Emergency Use Authorization: demonstrated during COVID-19 (Covishield, Covaxin). (5) Fixed-dose combination (FDC) rationalization: CDSCO requiring evidence of benefit for combinations. (6) SUGAM portal: single-window platform for all regulatory applications. Import of new drugs: Form 40 (application), evaluated by CDSCO, requires data from country of origin + Indian bridging studies (may be waived). Post-approval obligations: periodic safety update reports, pharmacovigilance, annual compliance reports.
- 8Drug Approval Comparison – India vs USA: India (CDSCO): Governing law: D&C Act 1940 + Rules 1945 + New Drugs & CT Rules 2019. Application: New Drug Application to DCGI. Data requirements: Schedule Y/CT Rules specifications. Clinical trials: may accept global data with/without Indian studies. Review timeline: variable (improving — 90-day target for CT approvals). Post-marketing: PvPI pharmacovigilance. Generic drugs: State level manufacturing license + CDSCO approval if new to India. USA (FDA): Governing law: FD&C Act 1938 + amendments. Application: NDA (new) / ANDA (generic). Data requirements: extensive (CTD format). Clinical trials: full Phase I-III in USA or accepted foreign data (per FDA standards). Review timeline: 10 months (standard) / 6 months (priority). Post-marketing: REMS, MedWatch. Generic drugs: ANDA with bioequivalence + ANDA suitability.
Learning Objectives
Exam Prep Questions
Q1. Who is the DCGI and what powers does this position have?
DCGI (Drugs Controller General of India) is the HEAD of CDSCO — the most senior drug regulatory official in India. The DCGI: (1) Approves or rejects new drug applications (the ONLY authority who can approve new drugs in India). (2) Grants clinical trial permissions. (3) Issues import licenses/registrations. (4) Can suspend/cancel manufacturing licenses (in coordination with states). (5) Can ban drugs deemed unsafe. (6) Represents India in international regulatory forums (ICH, WHO). (7) Chairs the New Drugs Advisory Committee. The DCGI is appointed by the Central Government and reports to the Directorate General of Health Services.
Q2. Why does India have a dual regulatory system?
India adopted a dual (Central + State) regulatory system because: (1) India is vast (28 states, 8 UTs) with thousands of pharmaceutical establishments — a single central authority cannot physically inspect and regulate all of them. (2) The D&C Act 1940 was designed with this division: Central for national-level decisions (new drug approval, standards), State for ground-level implementation (manufacturing/sale licensing, inspection). (3) Healthcare is a state subject in the Indian Constitution. The challenge: inconsistency between states. This is why reforms (Mashelkar Committee, SUGAM portal) aim for better coordination and harmonization while maintaining the dual structure.
Q3. What changed with the New Drugs and Clinical Trials Rules, 2019?
Major changes: (1) STREAMLINED TIMELINES: CDSCO must respond within 30 days (CT applications) to 90 days (new drug applications) — previously no defined timeline. (2) Clinical trial COMPENSATION: structured framework for compensating subjects for study-related injuries/death. (3) ACADEMIC clinical trials: relaxed requirements for investigator-initiated academic research. (4) Ethics committee REGISTRATION: mandatory registration of all ethics committees. (5) New trial CATEGORIES: bioavailability, bioequivalence, post-marketing surveillance explicitly defined. (6) GLOBAL data acceptance: CDSCO can accept global clinical trial data for approval (with/without Indian bridging). (7) ORPHAN drug provisions. (8) Emergency use authorization pathway. These rules replaced the outdated Schedule Y provisions.